Showing 1381-1390 of 2526 results for "".
- Alcon Unveils SMARTCataract DX and Ngenuity 1.5 at ESCRShttps://modernod.com/news/alcon-unveils-innovations-at-escrs-including-smartcataract-dx-and-ngenuity-15/2482433/Alcon is introducing new technologies at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting aimed at improving efficiency and outcomes in cataract surgery. Among the announcements are the unveiling of the SMARTCataract DX digital planning solution and the upgraded Nge
- Yale Study Uncovers How Brain Wiring Begins Before Birthhttps://modernod.com/news/yale-study-uncovers-how-brain-wiring-begins-before-birth/2482409/Researchers at Yale say they have uncovered how the brain begins to wire itself during early development, long before experiences or sensory inputs like sight come into play. The study, published this month in Science, reveals that brain cells start forming networks based on sp
- Eyedaptic Unveils AI-Powered Visual Assistant for People with Retinal Disordershttps://modernod.com/news/eyedaptic-unveils-eye6-with-ivy-ai-powered-visual-assistant-for-people-with-retinal-disorders/2482385/Eyedaptic unveiled the EYE6 with Ivy, a wearable vision aid designed to enhance vision and provide an AI-powered visual assistant. The EYE6 is the next generation of Eyedaptic’s smart glasses, which includes Ivy, an interactive visual assistant to help and
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgeryhttps://modernod.com/news/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-for-the-treatment-of-decreased-va-under-low-light-conditions-following-keratorefractive-surgery/2482227/Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 phase 3 registration study evaluating phentolamine ophthalmic solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery. The LY
- Brill Establishes Subsidiary in the United Stateshttps://modernod.com/news/brill-establishes-subsidiary-in-the-united-states/2482209/Brill, the global pharmaceutical company specializing in ophthalmology, announced the establishment of a subsidiary in the United States with headquarters in Miami, Florida, a manufacturing center in Boston, Massachusetts, and strategic locations for distributing healthcare solutions throughout t
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- Iridex 532 and Iridex 577 Lasers Launched in United Stateshttps://modernod.com/news/iridex-532-and-iridex-577-lasers-launched-in-united-states/2482054/Iridex announced the United States launch of its next-generation platform Iridex 532 and Iridex 577 lasers. According to the company, both lasers harness multiple treatment modes including continuous-wave and the company’s MicroPulse technology and an intuitive touchscreen interfa
- Harrow Launches Dry Eye Drug Vevye in the United Stateshttps://modernod.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available in the United States. It is indicated for treating the signs and symptoms of dry eye disease (DED). Vevye is the company’s nonpreserved, twice-daily dosed prescription drug based on a water free s
- Nidek Launches Mirante Scanning Laser Ophthalmoscope in the United Stateshttps://modernod.com/news/nidek-launches-mirante-scanning-laser-ophthalmoscope-in-the-united-states/2482052/Nidek announced the commercial launch of the Mirante Scanning Laser Ophthalmoscope (SLO) in the United States. The Mirante is a multimodal fundus-imaging platform that combines high-definition SLO and optical coherence tomography (OCT) with ultra-wide field imaging. The multimodal platf